Start · Publikationen

Publikationen

Konsolidierte Übersicht der Veröffentlichungen rund um Bone Sialoprotein (BSP) — geordnet nach den vier ABT-Projektlinien sowie nach grundlegender Biochemie und Knochenstoffwechsel.

Eigene Veröffentlichungen mit ABT-Beteiligung

  • Seibel MJ, Woitge HW, Pecherstorfer M, Karmatschek M, Horn E, Ludwig H, Armbruster FP, Ziegler R (1996). Serum immunoreactive bone sialoprotein as a new marker of bone turnover in metabolic and malignant bone disease. Journal of Clinical Endocrinology and Metabolism 81(9): 3289–3294.
  • Karmatschek M, Maier I, Seibel MJ, Woitge HW, Ziegler R, Armbruster FP (1997). Improved purification of human bone sialoprotein and development of a homologous radioimmunoassay. Clinical Chemistry 43(11): 2076–2082.
  • Withold W, Armbruster FP, Karmatschek M, Reinauer H (1997). Bone sialoprotein in serum of patients with malignant bone diseases. Clinical Chemistry 43(1): 85–91.
  • Bäuerle T, Adwan H, Kiessling F, Hilbig H, Armbruster FP, Berger MR (2005). Characterization of a rat model with site-specific bone metastasis induced by MDA-MB-231 breast cancer cells and its application to the effects of an antibody against bone sialoprotein. International Journal of Cancer 115(2): 177–186. DOI
  • Bäuerle T, Peterschmitt J, Hilbig H, Kiessling F, Armbruster FP, Berger MR (2006). Treatment of bone metastasis induced by MDA-MB-231 breast cancer cells with an antibody against bone sialoprotein. International Journal of Oncology 28(3): 573–583.
  • Zepp M, Armbruster FP, Berger MR (2010). Rat monoclonal antibodies against bone sialoprotein II inhibit tumor growth and osteolytic lesions in nude rats induced by MDA-MB-231 breast cancer cells. International Journal of Clinical Pharmacology and Therapeutics 48(7): 462–464.
  • Zepp M et al. (2017). IDK1 is a rat monoclonal antibody against hypoglycosylated bone sialoprotein with application as biomarker and therapeutic agent in breast cancer skeletal metastasis. Journal of Pathology — Clinical Research 4(1): 55–68.
  • Oremek GM et al. (2021). Die Knochenmarker BSP, CTX und NTX und deren Publikationscharakteristika im Rahmen einer bibliometrischen Analyse. Zentralblatt für Arbeitsmedizin, Arbeitsschutz und Ergonomie.
  • Kriegel A, Schlosser C, Habeck T, Dahmen C, Götz H, Clauder F, Armbruster FP et al. (2022). Bone Sialoprotein Immobilized in Collagen Type I Enhances Bone Regeneration In vitro and In vivo. International Journal of Bioprinting 8(3). DOI
  • Kriegel A et al. (2023). Bone Sialoprotein Immobilized in Collagen Type I Enhances Angiogenesis In Vitro and In Ovo. Polymers 15(4): 1007.

Tumordiagnostik & Serummarker

  • Bellahcène A, Merville MP, Castronovo V (1994). Expression of bone sialoprotein, a bone matrix protein, in human breast cancer. Cancer Research 54(11): 2823–2826.
  • Bellahcène A et al. (1996). Bone sialoprotein expression in primary human breast cancer is associated with bone metastases development. Journal of Bone and Mineral Research 11(5): 665–670.
  • Bellahcène A, Menard S et al. (1996). Expression of bone sialoprotein in primary human breast cancer is associated with poor survival. International Journal of Cancer 69(4): 350–353.
  • Bellahcène A et al. (1997). Expression of bone sialoprotein in human lung cancer. Calcified Tissue International 61(3): 183–188.
  • Bellahcène A et al. (1998). Ectopic expression of bone sialoprotein in human thyroid cancer. Thyroid 8(8): 637–641.
  • Diel IJ et al. (1999). Serum bone sialoprotein in patients with primary breast cancer is a prognostic marker for subsequent bone metastasis. Clinical Cancer Research 5(12): 3914–3919.
  • Waltregny D et al. (2000). Increased expression of bone sialoprotein in bone metastases compared with visceral metastases in human breast and prostate cancers. Journal of Bone and Mineral Research 15(5): 834–843.
  • Fedarko NS et al. (2001). Elevated serum bone sialoprotein and osteopontin in colon, breast, prostate, and lung cancer. Clinical Cancer Research 7(12): 4060–4066.
  • Carlinfante G et al. (2003). Differential expression of osteopontin and bone sialoprotein in bone metastasis of breast and prostate carcinoma. Clinical & Experimental Metastasis 20(5): 437–444.
  • Jung K et al. (2004). Comparison of 10 serum bone turnover markers in prostate carcinoma patients with bone metastatic spread. International Journal of Cancer 111(5): 783–791.
  • Loibl S et al. (2006). PTHrP and bone sialoprotein as prognostic markers for developing bone metastases in breast cancer patients. Zentralblatt für Gynäkologie 128(6): 330–335.
  • Papotti M et al. (2006). Bone sialoprotein is predictive of bone metastases in resectable non-small-cell lung cancer. Journal of Clinical Oncology 24(30): 4818–4824.
  • Jain A et al. (2009). Small integrin-binding proteins as serum markers for prostate cancer detection. Clinical Cancer Research 15(16): 5199–5207.
  • Joerger M, Huober J (2012). Diagnostic and prognostic use of bone turnover markers. Recent Results in Cancer Research 192: 197–223.
  • Luedde M et al. (2018). Elevated serum levels of bone sialoprotein during ICU treatment predict long-term mortality in critically ill patients. Scientific Reports 8(1): 9750.
  • Loosen SH et al. (2019). Elevated serum levels of bone sialoprotein (BSP) predict long-term mortality in patients with pancreatic adenocarcinoma. Scientific Reports 9(1): 1489.
  • Maaroufi A et al. (2020). Serum levels of bone sialoprotein, osteopontin, and β2-microglobulin in stage I of multiple myeloma. Journal of Cancer Research and Therapeutics 16(1): 98–101.

Tumortherapie & Knochenmetastasen

  • Sung V, Stubbs JT et al. (1998). Bone sialoprotein supports breast cancer cell adhesion proliferation and migration through differential usage of the αvβ3 and αvβ5 integrins. Journal of Cellular Physiology 176(3): 482–494.
  • Fedarko NS et al. (2000). Factor H binding to bone sialoprotein and osteopontin enables tumor cell evasion of complement-mediated attack. Journal of Biological Chemistry 275(22): 16666–16672.
  • Pécheur I et al. (2002). Integrin αvβ3 expression confers on tumor cells a greater propensity to metastasize to bone. FASEB Journal 16(10): 1266–1268.
  • Karadag A et al. (2004). Bone sialoprotein, matrix metalloproteinase 2, and αvβ3 integrin in osteotropic cancer cell invasion. Journal of the National Cancer Institute 96(12): 956–965.
  • Adwan H, Bäuerle TJ, Berger MR (2004). Downregulation of osteopontin and bone sialoprotein II is related to reduced colony formation and metastasis formation of MDA-MB-231 human breast cancer cells. Cancer Gene Therapy 11(2): 109–120.
  • Sharp JA et al. (2004). Transfection of MDA-MB-231 human breast carcinoma cells with bone sialoprotein (BSP) stimulates migration and invasion. Clinical & Experimental Metastasis 21(1): 19–29.
  • Nam J-S et al. (2006). Bone sialoprotein mediates the tumor cell-targeted prometastatic activity of TGF-β in a mouse model of breast cancer. Cancer Research 66(12): 6327–6335.
  • Tu Q et al. (2009). Targeted overexpression of BSP in osteoclasts promotes bone metastasis of breast cancer cells. Journal of Cellular Physiology 218(1): 135.
  • Elazar V et al. (2010). Sustained delivery and efficacy of polymeric nanoparticles containing osteopontin and bone sialoprotein antisenses in rats with breast cancer bone metastasis. International Journal of Cancer 126(7): 1749–1760.
  • Wang J et al. (2013). BSP gene silencing inhibits migration, invasion, and bone metastasis of MDA-MB-231BO human breast cancer cells. PLoS ONE 8(5): e62936.
  • Kruger TE et al. (2014). Bone sialoprotein and osteopontin in bone metastasis of osteotropic cancers. Critical Reviews in Oncology / Hematology 89(2): 330–341.
  • Kovacheva M et al. (2014). Sustained conditional knockdown reveals intracellular bone sialoprotein as essential for breast cancer skeletal metastasis. Oncotarget 5(14): 5510–5522.
  • Rustamov V et al. (2019). Bone Sialoprotein Shows Enhanced Expression in Early, High-Proliferation Stages of Three-Dimensional Spheroid Cell Cultures of Breast Cancer Cell Line MDA-MB-231. Frontiers in Oncology 9: 36.
  • Wang L et al. (2019). Bone sialoprotein–αvβ3 integrin axis promotes breast cancer metastasis to the bone. Cancer Science 110(10): 3157–3172.
  • Keller F et al. (2021). Extracellular Matrix Components Regulate Bone Sialoprotein Expression in MDA-MB-231 Breast Cancer Cells. Cells 10(6): 1304.
  • Wu K et al. (2021). Exosomal miR-19a and IBSP cooperate to induce osteolytic bone metastasis of estrogen receptor-positive breast cancer. Nature Communications 12(1): 5196.
  • Chen Y et al. (2021). IBSP, a potential recurrence biomarker, promotes the progression of colorectal cancer via Fyn/β-catenin signaling. Cancer Medicine 10(12): 4030–4045.
  • Chen W-C et al. (2023). Bone sialoprotein promotes lung cancer osteolytic bone metastasis via MMP14-dependent mechanisms. Biochemical Pharmacology 211: 115540.
  • Ma Y et al. (2023). High expression of integrin-binding sialoprotein (IBSP) is associated with poor prognosis of osteosarcoma. Aging 16(1): 28–42.
  • Kottmann V et al. (2024). Bone sialoprotein stimulates cancer cell adhesion through the RGD motif and the αvβ3 and αvβ5 integrin receptors. Oncology Letters 28(5): 542.
  • Kottmann V et al. (2026). Bone sialoprotein: a multifunctional regulator of bone remodelling and tumour progression. Bone Research 14(1): 11.

Implantatbeschichtung & Biomaterialien

  • O'Toole GC et al. (2004). Bone sialoprotein-coated femoral implants are osteoinductive but mechanically compromised. Journal of Orthopaedic Research 22(3): 641–646.
  • de Oliveira PT, Nanci A (2004). Nanotexturing of titanium-based surfaces upregulates expression of bone sialoprotein and osteopontin by cultured osteogenic cells. Biomaterials 25(3): 403–413.
  • Hilbig H et al. (2005). Effects of dental implant surfaces on the expression of bone sialoprotein in cells derived from human mandibular bone. Medical Science Monitor 11(4): BR111–115.
  • Hilbig H et al. (2007). Implant surface coatings with bone sialoprotein, collagen, and fibronectin and their effects on cells derived from human maxillar bone. European Journal of Medical Research 12(1): 6–12.
  • Graf H-L et al. (2008). Effect of bone sialoprotein and collagen coating on cell attachment to TICER and pure titanium implant surfaces. International Journal of Oral and Maxillofacial Surgery 37(7): 634–640.
  • Schaeren S et al. (2010). Effect of bone sialoprotein coating of ceramic and synthetic polymer materials on in vitro osteogenic cell differentiation and in vivo bone formation. Journal of Biomedical Materials Research Part A 92(4): 1461–1467.
  • Drevelle O et al. (2013). Effect of BMP-2 and/or BMP-9 on preosteoblasts attached to polycaprolactone functionalized by adhesive peptides derived from bone sialoprotein. Biomaterials 34(4): 1051–1062.
  • Baranowski A et al. (2016). Surface Functionalization of Orthopedic Titanium Implants with Bone Sialoprotein. PLoS ONE 11(4): e0153978.
  • Klein A et al. (2018). Effect of bone sialoprotein coated three-dimensional printed calcium phosphate scaffolds on primary human osteoblasts. Journal of Biomedical Materials Research Part B 106(7): 2565–2575.
  • Baranowski A et al. (2018). Evaluation of Bone Sialoprotein Coating of Three-Dimensional Printed Calcium Phosphate Scaffolds in a Calvarial Defect Model in Mice. Materials 11(11).
  • Klein A et al. (2020). Effect of bone sialoprotein coating on progression of bone formation in a femoral defect model in rats. European Journal of Trauma and Emergency Surgery 46(2): 277–286.
  • Carvalho MS et al. (2021). Bone Matrix Non-Collagenous Proteins in Tissue Engineering: Creating New Bone by Mimicking the Extracellular Matrix. Polymers 13(7): 1095.
  • Kriegel A et al. (2022). Bone Sialoprotein Immobilized in Collagen Type I Enhances Bone Regeneration In vitro and In vivo. International Journal of Bioprinting 8(3).
  • Kriegel A et al. (2023). Bone Sialoprotein Immobilized in Collagen Type I Enhances Angiogenesis In Vitro and In Ovo. Polymers 15(4): 1007.

Knochenstoffwechsel & BSP-Biologie

  • Fisher LW et al. (1990). Human bone sialoprotein. Deduced protein sequence and chromosomal localization. Journal of Biological Chemistry 265(4): 2347–2351.
  • Bianco P et al. (1991). Expression of bone sialoprotein (BSP) in developing human tissues. Calcified Tissue International 49(6): 421–426.
  • Hunter GK, Goldberg HA (1993). Nucleation of hydroxyapatite by bone sialoprotein. PNAS 90(18): 8562–8565.
  • Stubbs JT et al. (1997). Characterization of native and recombinant bone sialoprotein: delineation of the mineral-binding and cell adhesion domains and structural analysis of the RGD domain. Journal of Bone and Mineral Research 12(8): 1210–1222.
  • Ganss B, Kim RH, Sodek J (1999). Bone sialoprotein. Critical Reviews in Oral Biology and Medicine 10(1): 79–98.
  • Wuttke M et al. (2001). Structural characterization of human recombinant and bone-derived bone sialoprotein. Functional implications for cell attachment and hydroxyapatite binding. Journal of Biological Chemistry 276(39): 36839–36848.
  • Tye CE et al. (2003). Delineation of the hydroxyapatite-nucleating domains of bone sialoprotein. Journal of Biological Chemistry 278(10): 7949–7955.
  • Malaval L et al. (2008). Bone sialoprotein plays a functional role in bone formation and osteoclastogenesis. Journal of Experimental Medicine 205(5): 1145–1153.
  • Ogata Y (2008). Bone sialoprotein and its transcriptional regulatory mechanism. Journal of Periodontal Research 43(2): 127–135.
  • Boudiffa M et al. (2010). Bone sialoprotein deficiency impairs osteoclastogenesis and mineral resorption in vitro. Journal of Bone and Mineral Research 25(12): 2669–2679.
  • Wade-Gueye NM et al. (2010). Mice Lacking Bone Sialoprotein (BSP) Lose Bone after Ovariectomy. Endocrinology 151(11): 5103–5113.
  • Bouleftour W et al. (2016). The role of the SIBLING, Bone Sialoprotein in skeletal biology — Contribution of mouse experimental genetics. Matrix Biology 52–54: 60–77.
  • Foster BL et al. (2015). Mineralization defects in cementum and craniofacial bone from loss of bone sialoprotein. Bone 78: 150–164.
  • Chavez MB et al. (2023). Bone Sialoprotein Is Critical for Alveolar Bone Healing in Mice. Journal of Dental Research 102(2): 187–196.

SIBLING-Familie & verwandte Themen

  • Fisher LW, Fedarko NS (2003). Six Genes Expressed in Bones and Teeth Encode the Current Members of the SIBLING Family of Proteins. Connective Tissue Research 44(1): 33–40.
  • Fisher LW et al. (2004). Small Integrin Binding Ligand N-Linked Glycoprotein Gene Family Expression in Different Cancers. Clinical Cancer Research 10(24): 8501–8511.
  • Staines KA, MacRae VE, Farquharson C (2012). The importance of the SIBLING family of proteins on skeletal mineralisation and bone remodelling. Journal of Endocrinology 214(3): 241–255.
  • Lamour V et al. (2013). SIBLING proteins: molecular tools for tumor progression and angiogenesis. Médecine Sciences 29(11): 1018–1025.

Eine vollständige Literaturübersicht (Stand Mai 2026, ca. 200 Einträge) ist auf Anfrage verfügbar — bitte über die Kontaktseite anfordern.